Zenatane 30mg will also be supported by The Promius Promise,
a pharmacy service designed specifically to support
Zenatane prescribers and patients. The Promius Promise
program is designed to assist with patient education about
treatment requirements and deliver Zenatane within 24 hours
to US locations, at a reduced expense, for eligible patients.
Promius explains that, pursuant to the Promius Promise, eligible
patients will have a money saving rebate automatically
applied, and will receive free shipping anywhere in the US.
The Promius Promise will also assist with insurance questions
and challenges if necessary.
iCAD to Present Positive Four-year Data on Xoft
iCAD, Inc. is presenting new positive data from its longestrunning
non melanoma skin cancer (NMSC) clinical trial
to-date at this year’s American Academy of Dermatology
meeting. Results indicate that patients treated with the Xoft
System for NMSC experienced good to excellent cosmesis
with few reoccurrences to date.
The Xoft System is an isotope-free radiation treatment cleared
by the U.S. Food and Drug Administration and CE marked in the
EU for use anywhere in the body, including for the treatment
of early-stage breast cancer, gynecological cancers and nonmelanoma
skin cancer. It utilizes a proprietary miniaturized
x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and
organs. The Xoft System requires only minimal shielding and
therefore does not require room redesign or construction investment.
Minimal shielding also allows medical personnel
to remain in the room with the patient during treatment. The
mobility of the Xoft System makes it easy to treat patients at
multiple locations and to easily store the system when not in
use. Xoft is a wholly owned subsidiary of iCAD, Inc.
